BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 4, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models
June 5, 2024
No Comments
Hangzhou Adcoris BioPharma Co. Ltd. is developing ACR-246, a novel 5T4-targeted antibody-drug-conjugate (ADC), for the treatment of solid tumors.
BioWorld Science
Conferences
American Society of Clinical Oncology
Cancer
Antibody-drug conjugate
Immuno-oncology
